Lilly’s Lechleiter to chairman
Lilly CEO John Lechleiter assumes the added role of chairman of the board effective Jan. 1, 2009, succeeding Sidney Taurel, who will become chairman emeritus. The move completes the transition in the company's top management. Lechleiter succeeded Taurel as CEO in April (1"The Pink Sheet," Jan. 7, 2008, p. 10). Taurel has served as Lilly's chairman since 1999, following his appointment as CEO in 1998. Lechleiter, a 28-year veteran of the company, was appointed president and chief operating officer in 2005
You may also be interested in...
The appointment of Lilly President and Chief Operating Officer John Lechleiter to CEO should be a smooth transition in early 2008 when longtime chief exec Sidney Taurel retires
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.